BAKER & MCKENZIE

RECEIVED **CENTRAL FAX CENTER**

Facsimile Transmission

SEP 1 5 2005

Baker & McKenzie LLP 815 Connecticut Avenue, NW Washington, DC 20006-4078, USA

Tel: +1 202 452 7000 Fax: +1 202 452 7074 www.bakernet.com

Date

September 15, 2005

Phone

Fax

To

Mail Stop Amendment

703-308-4357

571-273-8300

From

W. Jackson Matney, Jr.

202-835-1678

202-452-7074

Client/Matter No. 95176562-004002

Re

Applicant: Lloyd Wolfinbarger, Jr.

Serial No.: 10/624,534 Filed: July 23, 2003

Title: Process for Decellularizing Soft-Tissue Engineered Medical Implants, and

Decellularized Soft-Tissue Medical Implants Produced Thereby

Pages (w/cover)

Please see attached Transmittal Form and Response To Restriction/Election Requirement for filing with the United States Patent and Trademark office today.

Privacy and Confidentiality Notice

The information contained in this facsimile is intended for the named recipients only, it may contain privileged and confidential information and if you are not an intended recipiént, you must not copy, distribute or take any action in reliance on it. If you have received this facsimile in error, please notify us immediately by a collect telephone call to +1 202 452 7026 or +1 202 452 7000 and return the original to the sender by mail. We will relimburse you for the

Baker & McKenzie LLP is a member of Baker & McKenzie International, a Swiss Verein.

PAGE 1/4 * RCVD AT 9/15/2005 1:27:09 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/24 * DNIS:2738300 * CSID: * DURATION (mm-ss):00-38

TRANSMITTAL FORM (to be used for all correspondence after initial filing)				Application Number Filing Date First Named Invento Art Unit Examiner Name	to a collect 1 Ji 1 1 1 1 1 1	PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031 and and Trademark Office; U.S. DEPARTMENT OF COMMERCE tion of information unless it displays a valid OMB control number. 0/624.634 uity 23, 2003 byd Wolfinbarger, Jr. 891					
Total Number of Pages In This Submission			Attorney Docket Nur	mber 8	85176562-004002						
Foe Transe	Fee Transmittal Form			Drawing(\$)			After Allowance Communication to TC				
l —	Fee Attached			Licensing-related Pape	ers.			Appea of App	l Communication to Board eals and Interferences		
Amendment/Reply After Final Affidavtis/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53				Petition Petition to Convert to a Provisional Application Power of Attorney, Rechange of Correspond Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table	vocation dence Ado	iness		(Appea Proprie Status	Communication to TC Notice, Brief, Reply Brief) etary Information Letter Enclosure(s) (please Identify :		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT											
Firm Name Baker & McKenzie Signature Stephanie Wardwell Printed name											
Stephanie Wardwell											
Date September 15, 2005				1.No. 48,025							
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Palents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature Karen L Huddon											
Typed or printed name Karen L. Hudson						j		Date	September 15, 2005		

This collection of Information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office. U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22383-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PAGE 2/4 * RCVD AT 9/15/2005 1:27:09 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/24 * DNIS:2738300 * CSID: * DURATION (mm-ss):00-38

RECEIVED CENTRAL FAX CENTER

SEP 1 5 2005

DOCKET NUMBER: 195176562-004002 (64230-00004USD1)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Lloyd Wolfinbarger, Jr.

Serial No.: 10/624,534

Filed: July 23, 2003

For: PROCESS FOR DECELLULARIZING SOFT-TISSUE ENGINEERED MEDICAL IMPLANTS, AND DECELLULARIZED SOFT-TISSUE MEDICAL IMPLANTS PRODUCED THEREBY

§

ş

Group Art Unit.: 1651

Examiner: Thomas D. Bradrick

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

CERTIFICATE OF MAILING 37 CFR 1.8

I hereby certify that this correspondence is being transmitted via facsimile io: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 22313-1450 on September 15, 2005.

Signature

RESPONSE TO RESTRICTION/ELECTION REQUIREMENT

This filing is in response to the restriction requirement mailed August 16, 2005, which has a shortened period for response of September 16, 2005. No fees are believed to be due at this time. Please charge any deficiency in fees to Deposit Account No. 3740-0355. Please consider the following remarks and election.

Restriction

The Examiner required election of one of the following eight groups:

- I. Claims 1, 2, 7-27 and 33-45 drawn to processes for preparing accellular soft tissue grafts involving treating extracted tissues with one or more anionic detergents.
- II. Claims 3-33, 42-45 and 93 drawn to processes for preparing acellular soft tissue grafts using induced pressure mediated flows of solution to extract, treat, and decontaminate tissue.
- III. Claims 46-54 drawn to decellularized soft tissue grafts.
- IV. Claim 55 drawn to a non-immunogenic, acellular soft tissue graft.

BEST AVAILABLE COPY